Low-FODMAP ranked first in every IBS comparison. No trial tested the part you do alone.

The low-FODMAP diet has better trial evidence behind it than any other dietary approach to irritable bowel syndrome, and the trials stop at exactly the point where most people's experience of the diet begins. A network meta-analysis published in Gut ranked it first for every endpoint it examined — and then noted that most of the trials were run in specialist clinics and that none studied the effects of reintroducing foods and personalising the diet afterwards [s1].

Both of those sentences are true at once, and the gap between them is the story.

What the analysis pooled

The researchers searched the medical literature through to 2 April 2021 for randomised controlled trials of a low-FODMAP diet in IBS, and identified 13 eligible trials covering 944 patients [s1]. Efficacy was judged by whether patients achieved improvement in global IBS symptoms, and separately in abdominal pain, abdominal bloating or distension, and bowel habit [s1].

A network meta-analysis was the right tool for a specific reason the authors give: individual trials had compared the diet against numerous different alternatives and control conditions, so nobody could say which comparator was the meaningful one [s1]. A network analysis pools those scattered head-to-head comparisons into a single ranking.

The result, expressed as the relative risk of symptoms not improving — so lower is better — was 0.67 (95% CI 0.48 to 0.91) for the low-FODMAP diet versus a habitual diet, with a P-score of 0.99 [s1]. It ranked first, and was superior to all other interventions studied [s1].

It also ranked first for abdominal pain severity, for abdominal bloating or distension severity, and for bowel habit — though for bowel habit specifically it was not statistically superior to any other intervention [s1]. Against the dietary advice issued by the British Dietetic Association and the National Institute for Health and Care Excellence, the low-FODMAP diet was superior for abdominal bloating or distension, with a relative risk of 0.72 (95% CI 0.55 to 0.94) [s1].

A finding worth pausing on: BDA/NICE dietary advice, the standard first-line dietary counselling in the UK, was not superior to any other intervention in any of the analyses [s1].

What the trials did not test

The authors' own conclusion carries the caveat that matters most. Most trials were based in secondary or tertiary care — specialist gastroenterology clinics, not general practice — and did not study the effects of FODMAP reintroduction and personalisation on symptoms [s1].

The low-FODMAP diet as designed is three phases: a period of restriction, a structured reintroduction of individual FODMAP groups to find which ones a given person reacts to, and a long-term personalised diet that restricts only those. The trial evidence covers the first phase. The second and third phases — the ones that determine whether someone ends up on a permanently narrow diet or a nearly normal one — have not been tested in this literature.

That is not a small omission. Restriction is the part with the nutritional and social cost, and it is also the part that a person can find and follow from an app or a printed list without supervision.

Where the guidelines put it

The ACG guideline recommends a limited trial of a low-FODMAP diet in patients with IBS to improve global symptoms — the word "limited" is doing work in a document that grades every recommendation [s2]. It sits alongside a short list of other endorsed options, including gut-directed psychotherapy and, for specific IBS subtypes, particular drug classes [s2].

The BSG guideline reached its dietary recommendations by updating a series of trial-based and network meta-analyses of dietary, pharmacological and psychological therapies, and graded each using GRADE [s3]. Its framing of IBS as a disorder of gut-brain interaction rather than a functional gastrointestinal disorder is relevant here too [s3]: a diet that reduces fermentable substrate is acting on one part of a system that the guideline itself describes as multi-component.

The honest summary

For short-term symptom relief in IBS, the low-FODMAP diet has the strongest randomised evidence of any dietary intervention, and it beat the standard alternative advice on bloating specifically [s1]. That is a real finding from 13 trials, not a marketing claim.

What has not been demonstrated is that following the restriction phase indefinitely is either necessary or safe, because that question was not asked. What has also not been demonstrated is that the results transfer from specialist clinics — where a dietitian supervises the protocol — to someone working from a list found online, because the trials were not run in that setting [s1].

The distance between "ranked first in a network meta-analysis" and "works when done alone, forever" is not a technicality. It is the entire untested portion of the intervention.

This article is informational and is not medical advice. Restrictive diets have nutritional consequences, and decisions about them belong with a reader and a clinician or registered dietitian.

Sources

• Efficacy of a low FODMAP diet in irritable bowel syndrome: systematic review and network meta-analysis — Gut, 2021-08-10
• ACG Clinical Guideline: Management of Irritable Bowel Syndrome — American Journal of Gastroenterology, 2020-12-14
• British Society of Gastroenterology guidelines on the management of irritable bowel syndrome — Gut, 2021-04-26